SCHEMBL16005133

SCHEMBL16005133

COc1cc(Br)ccc1S(N)(=O)=O

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.47
TSHR P16473 1/20 0.47
GLA P06280 1/20 0.47
PTGES2 Q9H7Z7 3/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 2/20 0.46
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA9 Q16790 3/20 0.46
TRPV4 Q9HBA0 1/20 0.43
WDR5 P61964 2/20 0.42
MYC P01106 1/20 0.42
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31556387 1.00 PKM (0.53) PKMSMN1; SMN2TSHRGLAPTGES2
SCHEMBL1137871 0.85 SMN1; SMN2 (0.59) PKMSMN1; SMN2TSHRGLAPTGES2
Hydrochloric Acid SCHEMBL27865616 0.84 SMN1; SMN2 (0.58) PKMSMN1; SMN2TSHRGLAPTGES2
Methane SCHEMBL25341724 0.84 SMN1; SMN2 (0.58) PKMSMN1; SMN2TSHRGLAPTGES2
SCHEMBL4573199 0.83 SMN1; SMN2 (0.50) SMN1; SMN2TSHRGLAGAATRPV4
SCHEMBL4018384 0.81 TRPV4 (0.66) SMN1; SMN2TSHRGLAGAATRPV4
SCHEMBL17315165 0.81 SMN1; SMN2 (0.47) SMN1; SMN2TSHRGLALMNAGAA
SCHEMBL20505498 0.81 LMNA (0.57) PKMSMN1; SMN2TSHRGLALMNA
SCHEMBL31050364 0.80 SMN1; SMN2 (0.46) SMN1; SMN2TSHRGLAGAATRPV4
SCHEMBL51171 0.79 MCOLN3 (0.55) PKMSMN1; SMN2TSHRPTGES2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099404-A1 SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER QUBIT PHARMACEUTICALS (FR) 2026-05-15 WO disclosed
EP-4741375-A1 SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER Qubit Pharmaceuticals (FR) 2026-05-13 EP disclosed
EP-4727939-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP disclosed
US-20250122152-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-04-17 US disclosed
WO-2024259116-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2024-12-19 WO disclosed
EP-2774916-B1 PHENOLSULFONIC ACID ARYL ESTER, DEVELOPING AGENT, AND HEAT-SENSITIVE RECORDING MATERIAL JUJO PAPER CO LTD (JP) 2016-05-25 EP disclosed
US-9073376-B2 Phenolsulfonic acid aryl ester, developing agent, and heat-sensitive recording material NIPPON PAPER INDUSTRIES CO., LTD. (JP) 2015-07-07 US disclosed
US-20140315713-A1 PHENOLSULFONIC ACID ARYL ESTER, DEVELOPING AGENT, AND HEAT-SENSITIVE RECORDING MATERIAL NIPPON PAPER INDUSTRIES CO., LTD. (JP) 2014-10-23 US disclosed
EP-2774916-A1 PHENOLSULFONIC ACID ARYL ESTER, DEVELOPING AGENT, AND HEAT-SENSITIVE RECORDING MATERIAL Nippon Paper Industries Co., Ltd. (JP) 2014-09-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315713-A1 PHENOLSULFONIC ACID ARYL ESTER, DEVELOPING AGENT, AND HEAT-SENSITIVE RECORDING MATERIAL ARSA, AHNAK, HSPA4L PKM 3520/4885SMN1; SMN2 1242/4885TSHR 4347/4885
US-20250122152-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT7 PKM 1693/4885SMN1; SMN2 1499/4885TSHR 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.